Remove 2022 Remove Doctors Remove Marketing Remove Testimonials
article thumbnail

How Lume Whole Body Deodorant Was Inspired by a Genetic Disease

PLOS: DNA Science

Among the barrage of drug ads for cancer, diabetes, weight loss and more are those for Lume , a “doctor-developed whole body deodorant.” ” The Patent Trail Rather than relying on social media, company websites, and testimonials, I consulted the Patent and Trademark database to reconstruct the story of invention.

Disease 88
article thumbnail

Another RICOdiculous Decision

Drug & Device Law

The drug is still on the market, and it has other risks that the FDA has found significantly more serious – requiring a boxed warning – than a three-one hundredths-of one-percent (0.0003) increase in absolute incidence of bladder cancer. 2022) (many other cases recognize this problem with class actions). E.g. , Laudato v.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interesting Pelvic Mesh Due Process Certiorari Petition

Drug & Device Law

2022 WL 3147194 (C.D. 2022), review denied (Cal. July 13, 2022). at 451-52; The evidence failed to establish the contents of the defendants’ oral marketing communications, and thereby failed to show those communications met the “likely” to deceive standard, id. Ethicon, Inc. Johnson & Johnson , 292 Cal. 3d 424 (Cal.

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

2023) (remote trial testimony cannot be compelled beyond Rule 45’s 100-mile limit on subpoenas) ( here ); Carson v. F-150 & Ranger Truck Fuel Economy Marketing & Sales Practices Litigation , 65 F.4th They excluded bogus expert testimony under Fed. Bonta , 85 F.4th 4th 1263 (9th Cir. 4th 1030 (9th Cir. Monsanto Co. ,

article thumbnail

Never Satisfied But Motion For New Trial Denied

Drug & Device Law

2775, 1:17-cv-00944, 2022 WL 171503 (D. 18, 2022), interesting not so much for the specific holdings but because of the insight the case provides into one of the more prevalent dynamics of modern MDLs. 2022 WL 171503, *1. First, plaintiffs complained about allegedly undisclosed opinion testimony offered by a defense expert.

Trials 59
article thumbnail

Confident Learned Intermediaries Defeat Warning Causation

Drug & Device Law

Thus a confident learned intermediary’s testimony will defeat causation as a matter of law by stating that, notwithstanding a poor result, the treatment provided was standard of care, and even in hindsight they would not do anything different. Confident learned intermediaries stand by their medical decisions. Medrano , 28 S.W.3d

article thumbnail

Another Reason Why The FDA, Not Litigants, Approves Products

Drug & Device Law

Doctors Who Perform Abortions: Their Characteristics & Patterns of Holding & Using Hospital Privileges,” 6. 9 (“Longitudinal” for the proposition that “adverse events from chemical abortion drugs can overwhelm the medical system and place ‘enormous pressure and stress’ on doctors during emergencies and complications”), at *14 n.22

FDA 59